PMID- 14984266
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20190818
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 21
IP  - 1
DP  - 2004 Jan
TI  - Enhancing immunogenicity and reducing dose of microparticulated synthetic 
      vaccines: single intradermal administration.
PG  - 121-6
AB  - PURPOSE: Our purpose was to evaluate the ability of a polymeric vehicle to 
      release a model synthetic vaccine to the skin in order to reach a potent 
      activation of the specific immune response. METHODS: The peptide-loaded 
      poly-D,L-lactide-co-glycolide acid (PLGA) microparticles were prepared by a 
      double emulsion technique and administered to Balb/c mice. The immune response 
      (antibody and T cell activation) obtained by the intradermal (i.d.) and the 
      subcutaneous (s.c.) routes was tested. RESULTS: When similar doses of 
      peptide-loaded microparticles were injected s.c. or i.d. in mice, the antipeptide 
      IgG antibody immune response was found to be significantly higher after i.d. 
      injection into the skin. We could also reduce the dose of antigen 10 times by the 
      i.d. route and find a similar antibody response to that obtained by the s.c. 
      immunization. At the lowest i.d. dose level, the IgG2a/IgG1 ratio was also 
      incremented and the IgE production decreased. The i.d. microparticles induced, at 
      both dose levels, a marked IFN-gamma secretion by peptide-stimulated splenocytes 
      and lymph node cells and a significant T cell proliferation in spleen cell 
      cultures. CONCLUSIONS: The results demonstrate that peptide-loaded microparticles 
      were efficiently administered by the i.d. route because lower doses were required 
      and powerful antibody and T cell responses were obtained compared to the 
      conventional s.c. administration.
FAU - Carcaboso, Angel M
AU  - Carcaboso AM
AD  - Pharmacy and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, 
      University of the Basque Country (UPV-EHU), Paseo de la Universidad no 7, 01006 
      Vitoria-Gasteiz, Spain.
FAU - Hernandez, Rosa M
AU  - Hernandez RM
FAU - Igartua, Manuela
AU  - Igartua M
FAU - Rosas, Jaiver E
AU  - Rosas JE
FAU - Patarroyo, Manuel E
AU  - Patarroyo ME
FAU - Pedraz, Jose L
AU  - Pedraz JL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Polymers)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (Vaccines, Synthetic)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Animals
MH  - Cell Division/immunology
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Administration Schedule
MH  - Injections, Intradermal
MH  - Injections, Subcutaneous
MH  - Lactic Acid/administration & dosage/immunology
MH  - Lymphocyte Activation/immunology
MH  - Lymphocytes/cytology/drug effects/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *Microspheres
MH  - Particle Size
MH  - Polyglycolic Acid/administration & dosage
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers/administration & dosage
MH  - Spleen/drug effects/immunology
MH  - Vaccines, Subunit/*administration & dosage/*immunology
MH  - Vaccines, Synthetic/*administration & dosage/*immunology
EDAT- 2004/02/27 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/02/27 05:00
PHST- 2004/02/27 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/02/27 05:00 [entrez]
AID - 10.1023/b:pham.0000012159.20895.5b [doi]
PST - ppublish
SO  - Pharm Res. 2004 Jan;21(1):121-6. doi: 10.1023/b:pham.0000012159.20895.5b.